BTRC and cancer: Abnormal expression of MDM2 has been observed in various human cancers, potentially resulting from gene amplification, transcriptional regulation, and post‐translational modifications.[46] Small molecule inhibitors of MDM2 have been investigated as potential therapies for cancer.[47] At the protein level, the stability of MDM2 is regulated by other ubiquitin ligases, such as β‐Trcp, which directly binds to MDM2, leading to its degradation.